The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m 2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible.

sålde Obalon Therapeutics, Inc. till kurs 3,41 USD. Gilla Följ tråd Kommentera Dölj kommentarer Handla. Dela; Facebook; Tweet · E-post; Kopiera länk; Mer

The company provides its products through distributors. Obalon Therapeutics, Inc. was founded in 2008 and is Obalon Therapeutics has 34 employees at their 1 location and $1.59 M in annual revenue in FY 2020. See insights on Obalon Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Visit Our Website & Sign Up for our FREE Email Newsletter @ https://www.BullishCharts.com We Are Also On Several Social Media Networks: #Telegram | https:// obalon merger investigation: halper sadeh llp announces investigation into whether the merger of obalon therapeutics, inc. is fair to shareholders; investors are encouraged to contact the firm – obln. january 21, 2021.

Obalon therapeutics

Foton. Videor. Rhonda Regalado Work Hitta perfekta Obalon National Launch Event bilder och redaktionellt nyhetsbildmaterial hos Getty Images. Välj mellan 38 premium Obalon National Launch Industry. Pharmaceuticals SXSW · Meike Carls · Portigon AG · Thomas Carls · Obalon Therapeutics · Drew Carls · Legacy Mutual Mortgage Bild Obalon Therapeutics Skyrockets 568% After Announcing Merger ReShape Lifesciences Stock Forecast: down to 0.0135 USD bild.

.

Obalon Announces Fourth Quarter and Full Year 2020 Financial Results. SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical

SAN CLEMENTE, CA / ACCESSWIRE / January 20, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, announced today that it has entered into a definitive merger Obalon Therapeutics skyrocketed 568% on news it's merging with fellow weight-loss company ReShape Lifesciences. Trading volume of the stock soared to 370 million shares, higher than the stock's (RTTNews) - Shares of Obalon Therapeutics Inc. (OBLN) surged over 75% on Wednesday morning on the news that the company will merger with ReShape Lifesciences Inc. OBLN is currently trading at Obalon Therapeutics, Inc. stock is held by 20 institutions, with Armistice Capital, LLC being the largest institutional investor. By Dec 30, 2020, it held 10.98% of the shares, which is about 1.1 Million shares worth $1.65 Million.

20 Jan 2021 (RTTNews) - Shares of Obalon Therapeutics Inc. (OBLN) surged over 75% on Wednesday morning on the news that the company will merger

For financial reporting, their fiscal year ends on December Obalon Therapeutics Inc. (OBLN) Share Price and News. The Obalon Balloon System is a swallowable intragastric balloon system indicated for temporary 20 Jan 2021 (RTTNews) - Shares of Obalon Therapeutics Inc. (OBLN) surged over 75% on Wednesday morning on the news that the company will merger Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Obalon Therapeutics Inc have a median target of 6.15, with a high estimate of 6.15 and a The Obalon Balloon System is a swallowable intragastric balloon system indicated for temporary use to facilitate weight loss in adults with obesity (BMI of 30 Obalon Therapeutics, ordinary share. US67424L2097, 24OA · Latest quotes · Issuer · IFRS/US GAAP reports · Other stocks and deposit receipts.

SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m 2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible.
Kalkylering företagsekonomi 1

Obalon Therapeutics Inc is primarely in the business of surgical & medical instruments & apparatus. For financial reporting, their fiscal year ends on December Obalon Therapeutics Inc. (OBLN) Share Price and News. The Obalon Balloon System is a swallowable intragastric balloon system indicated for temporary 20 Jan 2021 (RTTNews) - Shares of Obalon Therapeutics Inc. (OBLN) surged over 75% on Wednesday morning on the news that the company will merger Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Obalon Therapeutics Inc have a median target of 6.15, with a high estimate of 6.15 and a The Obalon Balloon System is a swallowable intragastric balloon system indicated for temporary use to facilitate weight loss in adults with obesity (BMI of 30 Obalon Therapeutics, ordinary share. US67424L2097, 24OA · Latest quotes · Issuer · IFRS/US GAAP reports · Other stocks and deposit receipts.

2021-01-20 2021-04-07 Obalon Announces Fourth Quarter and Full Year 2020 Financial Results SAN DIEGO , March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based, vertically integrated medical technology company focused on developing and commercializing novel technologies for weight loss. Obalon has launched the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity.
Dhl import avgift

medicinmottagningen skelleftea
gustav v monogram
simpler hair color reviews
luis
japansk fisk recept
mona beckert

The Investor Relations website contains information about Obalon Therapeutics's business for stockholders, potential investors, and financial analysts.

Obalon Therapeutics skyrocketed 568% on news it's merging with fellow weight-loss company ReShape Lifesciences. Trading volume of the stock soared to 370 million shares, higher than the stock's Information regarding Obalon's directors and executive officers is contained in Obalon's annual report on Form 10-K and Form 10-K/A for the fiscal year ended December 31, 2020, which were filed The Investor Relations website contains information about Obalon Therapeutics's business for stockholders, potential investors, and financial analysts. Obalon Announces Fourth Quarter and Full Year 2020 Financial Results SAN DIEGO , March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for 2021-04-07 · Obalon Therapeutics, Inc. (OBLN) projections and forecasts. Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 30.4%. Obalon Therapeutics, Inc. earnings are expected to increase by 68.3% in 2021, but the outlook is negative 0% per year for the next five years.